More wins but some setbacks for pharma in US AWP litigation
This article was originally published in Scrip
Executive Summary
New developments have taken place in ongoing cases regarding alleged fraud by pharma companies in the manipulation of average wholesale prices (AWP) sent to reporting services, otherwise. Both states and municipalities have sued the drug makers in what is known as the AWP litigation.